OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
250859

Saint Bella Group Ltd

Healthcare Facilities & ServicesVerified

Saint Bella Group Ltd maintains a strong liquidity position with a current ratio of 2.22 and cash and equivalents of CNY 549.65 million, indicating a solid ability to meet short-term obligations. The company's debt-to-equity ratio of 0.18 suggests a conservative capital structure, with long-term debt at CNY 178.08 million compared to total equity of CNY 983.87 million. Profitability metrics show a return on equity (ROE) of 41.46% and a return on assets (ROA) of 26.32%, both significantly above the industry median for Healthcare Facilities & Services. The net income of CNY 407.87 million and operating income of CNY 103.97 million reflect strong operational performance. The company's revenue is concentrated in maternal and childcare services, with postpartum centers and home care services forming the core of its operations. The geographic exposure is primarily within China, with no disclosed international revenue segments. Outlook for the current fiscal year indicates a positive growth trajectory, supported by strong demand for postpartum and home care services. Analysts project a mean price target of CNY 7.77, with a mean recommendation of 1.33 (strong buy to buy). Risk assessment reveals low liquidity and dilution risks, with no immediate filing-based flags detected. The company's conservative debt levels and strong cash reserves mitigate financial risk. No dilution pressure is expected in the near term, with no recent issuance or ATM/shelf disclosures indicating potential equity dilution. Recent filings and transcripts do not highlight any material events or strategic shifts. The company continues to focus on expanding its postpartum care and home care services, leveraging its brand portfolio to capture market share.

30-day price · 2508-0.59 (-13.3%)
Low$3.51High$4.60Close$3.84As of21 May, 00:00 UTC
Profile
CompanySaint Bella Group Ltd
Ticker2508.HK
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. Saint Bella Group Ltd operates in maternal and childcare services, offering postpartum care, home care, and food products under multiple brands including Saint Bella, Baby Bella, and GuangHeTang.

Classification. The company is classified under the Healthcare sector, specifically in the Healthcare Facilities & Services industry, with a confidence level of 0.92.

Saint Bella Group Ltd maintains a strong liquidity position with a current ratio of 2.22 and cash and equivalents of CNY 549.65 million, indicating a solid ability to meet short-term obligations. The company's debt-to-equity ratio of 0.18 suggests a conservative capital structure, with long-term debt at CNY 178.08 million compared to total equity of CNY 983.87 million. Profitability metrics show a return on equity (ROE) of 41.46% and a return on assets (ROA) of 26.32%, both significantly above the industry median for Healthcare Facilities & Services. The net income of CNY 407.87 million and operating income of CNY 103.97 million reflect strong operational performance. The company's revenue is concentrated in maternal and childcare services, with postpartum centers and home care services forming the core of its operations. The geographic exposure is primarily within China, with no disclosed international revenue segments. Outlook for the current fiscal year indicates a positive growth trajectory, supported by strong demand for postpartum and home care services. Analysts project a mean price target of CNY 7.77, with a mean recommendation of 1.33 (strong buy to buy). Risk assessment reveals low liquidity and dilution risks, with no immediate filing-based flags detected. The company's conservative debt levels and strong cash reserves mitigate financial risk. No dilution pressure is expected in the near term, with no recent issuance or ATM/shelf disclosures indicating potential equity dilution. Recent filings and transcripts do not highlight any material events or strategic shifts. The company continues to focus on expanding its postpartum care and home care services, leveraging its brand portfolio to capture market share.
Key takeaways
  • Saint Bella Group Ltd has a strong liquidity position with a current ratio of 2.22 and CNY 549.65 million in cash and equivalents.
  • The company's ROE of 41.46% and ROA of 26.32% indicate high profitability relative to industry standards.
  • Revenue is concentrated in maternal and childcare services, with a strong domestic focus in China.
  • Analysts project a mean price target of CNY 7.77, with a strong buy recommendation.
  • Low liquidity and dilution risks, with no immediate financial or equity dilution pressures.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyCNY
Revenue$1.05B
Gross profit$376.2M
Operating income$104.0M
Net income$407.9M
R&D
SG&A
D&A
SBC
Operating cash flow
CapEx
Free cash flow
Total assets$1.55B
Total liabilities$565.7M
Total equity$983.9M
Cash & equivalents$549.6M
Long-term debt$178.1M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$983.9M
Net cash$371.6M
Current ratio2.2
Debt/Equity0.2
ROA26.3%
ROE41.5%
Cash conversion
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Biotechnology · cohort 9 companies
Metric2508Activity
Op margin9.9%11.5% medp25 9.9% · p75 15.0%below median
Net margin39.0%8.6% medp25 6.3% · p75 12.4%top quartile
Gross margin36.0%28.8% medp25 28.8% · p75 28.8%top quartile
CapEx / revenue4.2% medp25 3.8% · p75 4.2%
Debt / equity18.0%71.3% medp25 60.7% · p75 71.3%bottom quartile
Observations
IR observations
Mean price target7.77 CNY
Median price target7.77 CNY
High price target7.90 CNY
Low price target7.64 CNY
Mean recommendation1.33 (1=strong buy, 5=strong sell)
Strong-buy count2.00
Buy count1.00
Hold count0.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate0.32 CNY
Last actual EPS0.27 CNY
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-07 05:00 UTC#7cf3c33a
Source: analysis-pipeline (hybrid)Generated: 2026-05-04 12:35 UTCJob: d122410a